Skip to Main Content

The Covid-19 pandemic has wreaked havoc across the globe — including upending the process of drug development. 

That has been especially true in clinical trials for oncology, which come with a complex set of considerations. Patients often have to come into the clinic or be hospitalized for treatment. They also have to be protected against possible infections that could devastate a weakened immune system. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!